SIDE EFFECTS
The following are described in greater detail in the Warnings and Precautions section.
- Hypersensitivity Reactions
- Seizure Potential
- Interaction with Valproic Acid
- Clostridioides difficile-Associated Diarrhea (CDAD)
- Caution with Intramuscular Administration
- Development of Drug-Resistant Bacteria
- Laboratory Tests
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adults Receiving INVANZ As A Treatment Regimen
Clinical trials enrolled 1954 patients treated with INVANZ; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial . Most adverse experiences reported in these clinical trials were described as mild to moderate in severity. INVANZ was discontinued due to adverse experiences in 4.7% of patients. Table 3 shows the incidence of adverse experiences reported in ≥2.0% of patients in these trials. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), and vaginitis in females (2.1%).
Table 1 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials
| Adverse Events | INVANZ* 1 g daily (N=802) |
Piperacillin/ Tazobactam* 3.375 g q6h (N=774) |
INVANZ† 1 g daily (N=1152) |
Ceftriaxone† 1 or 2 g daily (N=942) |
| Local: | ||||
| Infused vein complication | 7.1 | 7.9 | 5.4 | 6.7 |
| Systemic: | ||||
| Death | 2.5 | 1.6 | 1.3 | 1.6 |
| Edema/swelling | 3.4 | 2.5 | 2.9 | 3.3 |
| Fever | 5.0 | 6.6 | 2.3 | 3.4 |
| Abdominal pain | 3.6 | 4.8 | 4.3 | 3.9 |
| Hypotension | 2.0 | 1.4 | 1.0 | 1.2 |
| Constipation | 4.0 | 5.4 | 3.3 | 3.1 |
| Diarrhea | 10.3 | 12.1 | 9.2 | 9.8 |
| Nausea | 8.5 | 8.7 | 6.4 | 7.4 |
| Vomiting | 3.7 | 5.3 | 4.0 | 4.0 |
| Altered mental status‡ | 5.1 | 3.4 | 3.3 | 2.5 |
| Dizziness | 2.1 | 3.0 | 1.5 | 2.1 |
| Headache | 5.6 | 5.4 | 6.8 | 6.9 |
| Insomnia | 3.2 | 5.2 | 3.0 | 4.1 |
| Dyspnea | 2.6 | 1.8 | 1.0 | 2.4 |
| Pruritus | 2.0 | 2.6 | 1.0 | 1.9 |
| Rash | 2.5 | 3.1 | 2.3 | 1.5 |
| Vaginitis | 1.4 | 1.0 | 3.3 | 3.7 |
| * Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials † Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials ‡ Includes agitation, confusion, disorientation, decreased mental acuity, changed mental status, somnolence, stupor |
||||
In patients treated for complicated intra-abdominal infections, death occurred in 4.7% (15/316) of patients receiving INVANZ and 2.6% (8/307) of patients receiving comparator drug. These deaths occurred in patients with significant co-morbidity and/or severe baseline infections. Deaths were considered unrelated to study drugs by investigators.
In clinical trials, seizure was reported during study therapy plus 14-day follow-up period in 0.5% of patients treated with INVANZ, 0.3% of patients treated with piperacillin/tazobactam and 0% of patients treated with ceftriaxone.
Additional adverse experiences that were reported with INVANZ with an incidence >0.1% within each body system are listed below
Body as a Whole: abdominal distention, pain, chills, septicemia, septic shock, dehydration, gout, malaise, asthenia/fatigue, necrosis, candidiasis, weight loss, facial edema, injection site induration, injection site pain, extravasation, phlebitis/thrombophlebitis, flank pain, syncope
Cardiovascular System: heart failure, hematoma, chest pain, hypertension, tachycardia, cardiac arrest, bradycardia, arrhythmia, atrial fibrillation, heart murmur, ventricular tachycardia, asystole, subdural hemorrhage
Digestive System: acid regurgitation, oral candidiasis, dyspepsia, gastrointestinal hemorrhage, anorexia, flatulence, C. difficile-associated diarrhea, stomatitis, dysphagia, hemorrhoids, ileus, cholelithiasis, duodenitis, esophagitis, gastritis, jaundice, mouth ulcer, pancreatitis, pyloric stenosis
Musculoskeletal System: leg pain
Nervous System & Psychiatric: anxiety, nervousness, seizure , tremor, depression, hypesthesia, spasm, paresthesia, aggressive behavior, vertigo
Respiratory System: cough, pharyngitis, rales/rhonchi, respiratory distress, pleural effusion, hypoxemia, bronchoconstriction, pharyngeal discomfort, epistaxis, pleuritic pain, asthma, hemoptysis, hiccups, voice disturbance
Skin & Skin Appendage: erythema, sweating, dermatitis, desquamation, flushing, urticaria
Special Senses: taste perversion
Urogenital System: renal impairment, oliguria/anuria, vaginal pruritus, hematuria, urinary retention, bladder dysfunction, vaginal candidiasis, vulvovaginitis.
In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the adverse experience profile was generally similar to that seen in previous clinical trials.
Prophylaxis Of Surgical Site Infection Following Elective Colorectal Surgery
In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials. Table 4 shows the incidence of adverse experiences other than those previously described above for INVANZ that were reported regardless of causality in ≥2.0% of patients in this trial.
Table 2 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ for Prophylaxis of Surgical Site Infections Following Elective Colorectal Surgery
| Adverse Events | INVANZ 1g (N = 476) |
Cefotetan 2g (N = 476) |
| Anemia | 5.7 | 6.9 |
| Small intestinal obstruction | 2.1 | 1.9 |
| Pneumonia | 2.1 | 4.0 |
| Postoperative infection | 2.3 | 4.0 |
| Urinary tract infection | 3.8 | 5.5 |
| Wound infection | 6.5 | 12.4 |
| Wound complication | 2.9 | 2.3 |
| Atelectasis | 3.4 | 1.9 |
Additional adverse experiences that were reported in this prophylaxis trial with INVANZ, regardless of causality, with an incidence >0.5% within each body system are listed below:
Gastrointestinal Disorders: C. difficile infection or colitis, dry mouth, hematochezia
General Disorders and Administration Site Condition: crepitations
Infections and Infestations: cellulitis, abdominal abscess, fungal rash, pelvic abscess
Injury, Poisoning and Procedural Complications: incision site complication, incision site hemorrhage, intestinal stoma complication, anastomotic leak, seroma, wound dehiscence, wound secretion
Musculoskeletal and Connective Tissue Disorders: muscle spasms
Nervous System Disorders: cerebrovascular accident
Renal and Urinary Disorders: dysuria, pollakiuria
Respiratory, Thoracic and Mediastinal Disorders: crackles lung, lung infiltration, pulmonary congestion, pulmonary embolism, wheezing.
Pediatric Patients Receiving INVANZ As A Treatment Regimen
Clinical trials enrolled 384 patients treated with INVANZ; in some of the clinical trials, parenteral therapy was followed by a switch to an appropriate oral antimicrobial . The overall adverse experience profile in pediatric patients is comparable to that in adult patients. Table 5 shows the incidence of adverse experiences reported in ≥2.0% of pediatric patients in clinical trials. The most common drug-related adverse experiences in pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (6.5%), infusion site pain (5.5%), infusion site erythema (2.6%), vomiting (2.1%).
Table 3 : Incidence (%) of Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials
| Adverse Events | INVANZ*† (N=384) |
Ceftriaxone* (N=100) |
Ticarcillin/ Clavulanate† (N=24) |
| Local: | |||
| Infusion Site Erythema | 3.9 | 3.0 | 8.3 |
| Infusion Site Pain | 7.0 | 4.0 | 20.8 |
| Systemic: | |||
| Abdominal Pain | 4.7 | 3.0 | 4.2 |
| Constipation | 2.3 | 0.0 | 0.0 |
| Diarrhea | 11.7 | 17.0 | 4.2 |
| Loose Stools | 2.1 | 0.0 | 0.0 |
| Vomiting | 10.2 | 11.0 | 8.3 |
| Pyrexia | 4.9 | 6.0 | 8.3 |
| Upper Respiratory Tract Infection | 2.3 | 3.0 | 0.0 |
| Headache | 4.4 | 4.0 | 0.0 |
| Cough | 4.4 | 3.0 | 0.0 |
| Diaper Dermatitis | 4.7 | 4.0 | 0.0 |
| Rash | 2.9 | 2.0 | 8.3 |
| * Includes Phase IIb Complicated skin and skin structure infections, Community acquired pneumonia and Complicated urinary tract infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g or ceftriaxone 50 mg/kg/day IV in two divided doses up to a maximum of 2 g, and patients 13 to 17 years of age received INVANZ 1 g IV daily or ceftriaxone 50 mg/kg/day IV in a single daily dose. † Includes Phase IIb Acute pelvic infections and Complicated intra-abdominal infections trials in which patients 3 months to 12 years of age received INVANZ 15 mg/kg IV twice daily up to a maximum of 1 g and patients 13 to 17 years of age received INVANZ 1 g IV daily or ticarcillin/clavulanate 50 mg/kg for patients <60 kg or ticarcillin/clavulanate 3.0 g for patients >60 kg, 4 or 6 times a day. |
|||
Additional adverse experiences that were reported with INVANZ with an incidence >0.5% within each body system are listed below:
Gastrointestinal Disorders: nausea
General Disorders and Administration Site Condition: hypothermia, chest pain, upper abdominal pain; infusion site pruritus, induration, phlebitis, swelling, and warmth
Infections and Infestations: candidiasis, oral candidiasis, viral pharyngitis, herpes simplex, ear infection, abdominal abscess
Metabolism and Nutrition Disorders: decreased appetite
Musculoskeletal and Connective Tissue Disorders: arthralgia
Nervous System Disorders: dizziness, somnolence
Psychiatric Disorders: insomnia
Reproductive System and Breast Disorders: genital rash
Respiratory, Thoracic and Mediastinal Disorders: wheezing, nasopharyngitis, pleural effusion, rhinitis, rhinorrhea
Skin and Subcutaneous Tissue Disorders: dermatitis, pruritus, rash erythematous, skin lesion
Vascular Disorders: phlebitis.
Post-Marketing Experience
The following additional adverse reactions have been identified during the post-approval use of INVANZ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal Disorders: teeth staining
Immune System Disorders: anaphylaxis including anaphylactoid reactions
Musculoskeletal and Connective Tissue Disorders: muscular weakness
Nervous System Disorders: coordination abnormal, depressed level of consciousness, dyskinesia, gait disturbance, myoclonus, tremor, encephalopathy (recovery was prolonged in patients with renal impairment)
Psychiatric Disorders: altered mental status (including aggression, delirium), hallucinations
Skin and Subcutaneous Tissue Disorders: Acute Generalized Exanthematous Pustulosis (AGEP), Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome), hypersensitivity vasculitis
Adverse Laboratory Changes In Clinical Trials
Adults Receiving INVANZ As Treatment Regimen
Laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ in clinical trials are presented in Table 6. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of adult patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were ALT increased (6.0%), AST increased (5.2%), serum alkaline phosphatase increased (3.4%), and platelet count increased (2.8%). INVANZ was discontinued due to laboratory adverse experiences in 0.3% of patients.
Table 4 : Incidence* (%) of Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Adult Patients Treated With INVANZ in Clinical Trials
| Adverse laboratory experiences | INVANZ‡ 1 g daily (n†=766) |
Piperacillin/ Tazobactam‡ 3.375 g q6h (n†=755) |
INVANZ§ 1 g daily (n†=1122) |
Ceftriaxone§ 1 or 2 g daily (n†=920) |
| ALT increased | 8.8 | 7.3 | 8.3 | 6.9 |
| AST increased | 8.4 | 8.3 | 7.1 | 6.5 |
| Serum alkaline phosphatase increased | 6.6 | 7.2 | 4.3 | 2.8 |
| Eosinophils increased | 1.1 | 1.1 | 2.1 | 1.8 |
| Hematocrit decreased | 3.0 | 2.9 | 3.4 | 2.4 |
| Hemoglobin decreased | 4.9 | 4.7 | 4.5 | 3.5 |
| Platelet count increased | 6.5 | 6.3 | 4.3 | 3.5 |
| Urine RBCs increased | 2.5 | 2.9 | 1.1 | 1.0 |
| Urine WBCs increased | 2.5 | 3.2 | 1.6 | 1.1 |
| * Number of patients with laboratory adverse experiences/Number of patients with the laboratory test † Number of patients with one or more laboratory tests ‡ Includes Phase IIb/III Complicated intra-abdominal infections, Complicated skin and skin structure infections and Acute pelvic infections trials § Includes Phase IIb/III Community acquired pneumonia and Complicated urinary tract infections, and Phase IIa trials |
||||
Additional laboratory adverse experiences that were reported during therapy in >0.1% of patients treated with INVANZ in clinical trials include: increases in serum creatinine, serum glucose, BUN, total, direct and indirect serum bilirubin, serum sodium and potassium, PT and PTT; decreases in serum potassium, serum albumin, WBC, platelet count, and segmented neutrophils.
In a clinical trial for the treatment of diabetic foot infections in which 289 adult diabetic patients were treated with INVANZ, the laboratory adverse experience profile was generally similar to that seen in previous clinical trials.
Prophylaxis Of Surgical Site Infection following Elective Colorectal Surgery
In a clinical trial in adults for the prophylaxis of surgical site infection following elective colorectal surgery in which 476 patients received a 1 g dose of INVANZ 1 hour prior to surgery and were then followed for safety 14 days post-surgery, the overall laboratory adverse experience profile was generally comparable to that observed for INVANZ in previous clinical trials.
Pediatric Patients Receiving INVANZ As A Treatment Regimen
Laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ in clinical trials are presented in Table 7. Drug-related laboratory adverse experiences that were reported during therapy in ≥2.0% of pediatric patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, in clinical trials were neutrophil count decreased (3.0%), ALT increased (2.2%), and AST increased (2.1%).
Table 5 : Incidence* (%) of Specific Laboratory Adverse Experiences Reported During Study Therapy Plus 14-Day Follow-Up in ≥2.0% of Pediatric Patients Treated With INVANZ in Clinical Trials
| Adverse laboratory experiences | INVANZ (n†=379) |
Ceftriaxone (n†=97) |
Ticarcillin/ Clavulanate (n†=24) |
| ALT Increased | 3.8 | 1.1 | 4.3 |
| AST Increased | 3.8 | 1.1 | 4.3 |
| Neutrophil Count Decreased | 5.8 | 3.1 | 0.0 |
| * Number of patients with laboratory adverse experiences/Number of patients with the laboratory test; where at least 300 patients had the test † Number of patients with one or more laboratory tests |
|||
Additional laboratory adverse experiences that were reported during therapy in >0.5% of patients treated with INVANZ in clinical trials include: alkaline phosphatase increased, eosinophil count increased, platelet count increased, white blood cell count decreased and urine protein present.
SRC: NLM .